Cardiac Science 8-K Cardiac Science Reports Record Revenue Raises 2008 Guidance

Exhibit 99.1

CARDIAC SCIENCE REPORTS RECORD REVENUE
RAISES 2008 GUIDANCE

Second quarter revenue up 16% to $52.1 million
International product sales double
EPS of $0.10; Operating cash flow of $6.3 million

Bothell, WA — July 29, 2008 —Cardiac Science Corporation [NASDAQ: CSCX], a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced revenue for the quarter ended June 30, 2008 was $52.1 million, an increase of 16% over the prior year period.

Revenue growth resulted from increases in defibrillation sales of 32% and service revenue of 19%, offsetting a decrease in cardiac monitoring sales of 7%. Of particular note, total international product sales doubled, increasing 113% over the prior year’s second quarter, driven primarily by strong automated external defibrillator (AED) sales. The Company also re-commenced hospital defibrillator shipments in the second quarter, which contributed as expected to the overall sales results.

The Company reported net income of $2.3 million, or $0.10 per diluted share in the second quarter, compared to net income of $4.5 million, or $0.19 per share in the second quarter of 2007. Prior year net income included a $6.0 million non-cash gain from a litigation settlement and $2.0 million in litigation-related expenses in that quarter.

Net income for the second quarter of 2008 was up by 32% over pro forma net income for the second quarter of 2007, which would have been $1.7 million, excluding the effect of the above-mentioned litigation items, net of income taxes.

Second Quarter Financial Results

Second quarter revenue of $52.1 million represented an increase of 16% over the $44.9 million in revenue reported in the second quarter of 2007.

The increase in defibrillation revenue was driven primarily by strong global AED sales. International AED sales were up 120%, with increases in most international areas, particularly Asia and Europe. While there was a 22% decline in domestic AED sales compared with the exceptional results of the prior year’s quarter, which included a mandated multi-million dollar school deployment, domestic AED sales did increase sequentially compared with the first quarter of 2008.

The Company believes general economic concerns are continuing to influence buying activity in the cardiac monitoring portion of the business. Total cardiac monitoring sales declined 7% during the quarter, however, total year to date cardiac monitoring sales are essentially flat when compared with the same period last year.

The increase in service revenue of 19% reflected continued growth in both global AED program management and cardiac monitoring contract sales.

Second quarter gross margin was 49.8%, an increase over the year-ago gross margin of 48.5%. This improvement was due to higher overall volume, favorable product mix, improvements in service gross margin, and the continuing success of cost reduction and manufacturing efficiency initiatives.

Operating expenses in the second quarter of 2008 were $22.2 million, or 42.6% of revenue. This compares to operating expenses of $15.5 million for the second quarter of 2007, which benefited from the net gain on litigation-related items mentioned above. Excluding the effect of the litigation items, pro forma operating expenses would have been $19.5 million, or 43.4% of revenue. Compared to the prior year pro forma results, the increase in current period operating expenses reflects an increase in the pace of our research and development activities to contribute to future product releases, higher sales commissions and other costs associated with our overall growth in revenue.

Operating income in the second quarter was $3.8 million. Reported operating income in the second quarter of the prior year was $6.3 million, including the net gain from litigation items. Excluding this gain, prior year pro forma second quarter operating income was $2.3 million. When compared to prior year pro forma results, current period operating income improved 64%, and current period operating margin increased from 5.1% to 7.2%.

Net income for the second quarter was $2.3 million, or $0.10 per diluted share, a 32% increase over pro forma net income of $1.7 million or $0.07 per diluted share last year, excluding the litigation-related items.

EBITDA was $5.2 million for the second quarter of 2008. Adjusted EBITDA, which excludes stock-based compensation expense and the net gain from litigation-related items, was $5.6 million, or 11% of revenue, compared to $4.9 million, or 11% of revenue, for the second quarter of 2007.

The Company generated $6.3 million in cash from operating activities during the quarter and had $27.7 million in cash and short-term investments as of June 30, 2008.

“Our strong second quarter revenue growth reflects the continued expansion of AED deployments globally and our ability to capture significant share in this growing market. Our international defibrillation performance was truly exceptional. We are also quite pleased to be experiencing the continued improvement in the Service areas and to be shipping the hospital defibrillator product again,” said John Hinson, president and chief executive officer.

Outlook

The Company updated its full-year guidance for 2008 and now expects revenue for 2008 to be in a range between $205 and $210 million, representing growth of 13% to 15% over 2007 and up from the 10% growth rate the Company had previously expected. The increase in the Company’s expectations is driven by higher growth in international AED revenues, meaningful revenue from the hospital defibrillator product and continued strength in the Company’s service offerings.

Net income, inclusive of an estimated income tax rate of 37%, was previously expected to be in a range between $8 and $9 million, or between $0.34 and $0.39 per share. In light of

the increase in expected revenue, as well as the Company’s intention to continue to increase its spending on R&D, the Company now expects net income to be in a range between $8.75 and $9.5 million, or between $0.38 and $0.41 per share. Adjusted EBITDA is expected to be in a range between 11.0% and 11.5% of revenue.

Non-GAAP and Pro Forma Financial Information

This news release contains a discussion of EBITDA, Adjusted EBITDA, Pro Forma Operating Income, and Pro Forma Net Income, which are non-GAAP financial measures provided as a complement to results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The term “EBITDA” refers to a financial measure defined as earnings before net interest, income taxes, depreciation, and amortization. “Adjusted EBITDA” refers to EBITDA before stock-based compensation and litigation expense. Pro Forma Operating Income refers to Operating Income before litigation expenses. Pro Forma Net Income refers to Net Income before litigation expenses and the related tax effect of these expenses. None of these measures are a substitute for measures determined in accordance with GAAP, and may not be comparable to the same measures as reported by other companies. EBITDA, Adjusted EBITDA, Pro Forma Operating Income, and Pro Forma Net Income are an integral part of the internal management reporting and planning process and are the primary measures used by management to evaluate the operating performance of the Company. The components of these measures include the key revenue and expense items for which operating managers are responsible and upon which their performance is evaluated. The Company also uses Adjusted EBITDA for planning purposes and in presentations to its board of directors. Reconciliations of net income, the most comparable GAAP measure, to EBITDA, Adjusted EBITDA, Pro Forma Operating Income, and Pro Forma Net Income are contained in this press release.

Conference Call Information

Cardiac Science will conduct a conference call at 4:30 p.m. Eastern Time today to discuss the Company’s financial results for the second quarter. The call will be hosted by John Hinson, chief executive officer, and Mike Matysik, senior vice president and chief financial officer.

To access the conference call, please dial 800.257.3401. International participants can call 303.262.2125. The call will also be web cast live atwww.cardiacscience.com. An audio replay of the call will be available for 7 days following the call at (800) 405-2236 for U.S. callers or 303.590.3000 for those calling outside the U.S. The password required to access the replay is 11117631#. An audio archive will be available atwww.cardiacscience.com for 90 days following the call.

For more information,

Company Contact:	Investor Contact:	Media Contact:
Mike Matysik Cardiac Science Corporation Sr. Vice President and CFO 425.402.2009	Jenifer Kirtland EVC Group, Inc. 415.896.6820	Christopher Gale EVC Group, Inc. 201.646.5431 203.570.4681 cgale@evcgroup.com

About Cardiac Science Corporation

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS),

electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^®brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visitwww.cardiacscience.com.

Forward Looking Statements

This press release contains forward-looking statements. The word “believe,” “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation’s future revenue, earnings, earnings per share, cash flow, gross margins, Adjusted EBITDA, its ability to expand its distribution partnerships and revenue derived from them, product releases and revenue derived from them and possible acquisitions. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2007. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

(Tables to Follow)

Cardiac Science Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)

	Three Months Ended June 30,
	2008						2007
	$			%			$			%
Revenues:
Cardiac monitoring products	$	15,574			29.9	%	$	16,704			37.2	%
Defibrillation products		31,683			60.8	%		24,083			53.7	%
Total product revenues		47,257			90.6	%		40,787			90.9	%
Service		4,875			9.4	%		4,102			9.1	%
Total revenues		52,132			100.0	%		44,889			100.0	%
Cost of Revenues:
Products		22,929			48.5	%		19,949			48.9	%
Service		3,240			66.5	%		3,174			77.4	%
Total cost of revenues		26,169			50.2	%		23,123			51.5	%
Gross Profit:
Products		24,328			51.5	%		20,838			51.1	%
Service		1,635			33.5	%		928			22.6	%
Gross profit		25,963			49.8	%		21,766			48.5	%
Operating Expenses:
Research and development		3,796			7.3	%		3,090			6.9	%
Sales and marketing		13,047			25.0	%		11,445			25.5	%
General and administrative		5,347			10.3	%		4,933			11.0	%
Litigation and related expenses		—			0.0	%		2,029			4.5	%
Licensing income and litigation settlement		—			0.0	%		(6,000	)		-13.4	%
Total operating expenses		22,190			42.6	%		15,497			34.5	%
Operating income		3,773			7.2	%		6,269			14.0	%
Other Income:
Interest income, net		163			0.3	%		74			0.2	%
Other income (expense), net		(125	)		-0.2	%		327			0.7	%
Total other income		38			0.1	%		401			0.9	%
Income before income tax expense and minority interests		3,811			7.3	%		6,670			14.9	%
Income tax expense		(1,407	)		-2.7	%		(2,155	)		-4.8	%
Income before minority interests		2,404			4.6	%		4,515			10.1	%
Minority interests		(118	)		-0.2	%		15			0.0	%
Net income	$	2,286			4.4	%	$	4,530			10.1	%
Net income per share — basic	$	0.10					$	0.20
Net income per share — diluted	$	0.10					$	0.19
Weighted average shares outstanding — basic		22,806,307						22,689,932
Weighted average shares outstanding — diluted		23,246,240						23,283,471

Cardiac Science Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)

	Six Months Ended June 30,
	2008						2007
	$			%			$			%
Revenues:
Cardiac monitoring products	$	33,297			32.9	%	$	33,356			38.5	%
Defibrillation products		58,299			57.7	%		45,122			52.1	%
Total product revenues		91,596			90.6	%		78,478			90.7	%
Service		9,495			9.4	%		8,081			9.3	%
Total revenues		101,091			100.0	%		86,559			100.0	%
Cost of Revenues:
Products		44,461			48.5	%		38,786			49.4	%
Service		6,469			68.1	%		6,127			75.8	%
Total cost of revenues		50,930			50.4	%		44,913			51.9	%
Gross Profit:
Products		47,135			51.5	%		39,692			50.6	%
Service		3,026			31.9	%		1,954			24.2	%
Gross profit		50,161			49.6	%		41,646			48.1	%
Operating Expenses:
Research and development		7,659			7.6	%		6,072			7.0	%
Sales and marketing		25,236			25.0	%		22,553			26.1	%
General and administrative		10,472			10.4	%		9,445			10.9	%
Litigation and related expenses		—			0.0	%		3,717			4.3	%
Licensing income and litigation settlement		—			0.0	%		(6,000	)		-6.9	%
Total operating expenses		43,367			42.9	%		35,787			41.3	%
Operating income		6,794			6.7	%		5,859			6.8	%
Other Income:
Interest income, net		278			0.3	%		96			0.1	%
Other income, net		86			0.1	%		452			0.5	%
Total other income		364			0.4	%		548			0.6	%
Income before income tax expense and minority interests		7,158			7.1	%		6,407			7.4	%
Income tax expense		(2,647	)		-2.6	%		(2,080	)		-2.4	%
Income before minority interests		4,511			4.5	%		4,327			5.0	%
Minority interests		(171	)		-0.2	%		37			0.0	%
Net income	$	4,340			4.3	%	$	4,364			5.0	%
Net income per share — basic	$	0.19					$	0.19
Net income per share — diluted	$	0.19					$	0.19
Weighted average shares outstanding — basic		22,729,858						22,651,053
Weighted average shares outstanding — diluted		23,277,135						23,187,206

Cardiac Science Corporation and Subsidiaries
Condensed Consolidated Balance Sheets (unaudited)
(in thousands)

	June 30, 2008		December 31, 2007
ASSETS
Current Assets:
Cash and cash equivalents	$	27,721	$	20,159
Short-term investments		—		350
Accounts receivable, net		29,439		29,439
Inventories		22,565		21,794
Deferred income taxes, net		9,582		9,558
Prepaid expenses and other current assets		3,113		2,509
Total current assets		92,420		83,809
Other assets		438		125
Machinery and equipment, net of accumulated depreciation		5,244		5,056
Deferred income taxes, net		27,826		30,288
Intangible assets, net of accumulated amortization		33,281		35,053
Investment in unconsolidated entities		655		727
Goodwill		107,613		107,613
Total assets	$	267,477	$	262,671
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	12,622	$	12,792
Accrued liabilities		10,430		11,075
Warranty liability		3,549		3,211
Deferred revenue		7,651		8,141
Total current liabilities		34,252		35,219
Other liabilities		—		54
Total liabilities		34,252		35,273
Minority interests		298		127
Shareholders’ Equity		232,927		227,271
Total liabilities and shareholders’ equity	$	267,477	$	262,671

Cardiac Science Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)

	Three Months Ended
	June 30,
	2008			2007
Operating Activities:
Net income	$	2,286		$	4,530
Adjustments to reconcile net income to cash provided by operating activities:
Licensing income and litigation settlement		—			(6,000	)
Stock-based compensation		488			562
Depreciation and amortization		1,624			1,706
Loss on disposal of machinery and equipment		—			1
Deferred income taxes		1,292			2,027
Minority interests		118			(16	)
Changes in operating assets and liabilities, net of business acquired:
Accounts receivable, net		2,688			(102	)
Inventories		(141	)		(1,934	)
Prepaid expenses and other assets		(61	)		(432	)
Accounts payable		(1,857	)		372
Accrued liabilities		955			1,904
Warranty liability		102			297
Deferred revenue		(1,160	)		460
Net cash provided by operating activities		6,334			3,375
Investing Activities:
Purchases of short-term investments		—			(395	)
Maturities of short-term investments		—			149
Purchases of patents as part of litigation settlement		—			(1,000	)
Purchases of machinery and equipment		(1,008	)		(494	)
Cash paid for acquisitions		(268	)		(292	)
Net cash used in investing activities		(1,276	)		(2,032	)
Financing Activities:
Proceeds from exercise of stock options and issuance of shares under employee purchase plan		173			387
Net cash provided by financing activities		173			387
Net change in cash and cash equivalents		5,231			1,730
Cash and cash equivalents, beginning of period		22,490			12,091
Cash and cash equivalents, end of period	$	27,721		$	13,821

Cardiac Science Corporation and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)
(in thousands)

	Six Months Ended
	June 30,
	2008			2007
Operating Activities:
Net income	$	4,340		$	4,364
Adjustments to reconcile net income to cash provided by operating activities:
Licensing income and litigation settlement		—			(6,000	)
Depreciation and amortization		3,233			3,312
Deferred income taxes		2,462			1,952
Stock-based compensation		1,046			1,175
Minority interests		171			(38	)
Loss on disposal of machinery and equipment		—			4
Changes in operating assets and liabilities, net of business acquired:
Accounts receivable, net		(313	)		(360	)
Inventories		(749	)		(2,541	)
Prepaid expenses and other assets		(624	)		(1,016	)
Accounts payable		(236	)		2,555
Accrued liabilities		(384	)		1,266
Warranty liability		338			373
Deferred revenue		(490	)		595
Net cash flows provided by operating activities		8,794			5,641
Investing Activities:
Purchases of short-term investments		—			(544	)
Maturities of short-term investments		350			696
Purchase of patents as part of litigation settlement		—			(1,000	)
Purchases of machinery and equipment		(1,442	)		(822	)
Cash paid for acquisitions		(424	)		(562	)
Net cash flows used in investing activities		(1,516	)		(2,232	)
Financing Activities:
Proceeds from exercise of stock options and issuance of shares under employee purchase plan		346			601
Minimum tax withholding on restricted stock awards		(62	)		(8	)
Net cash flows provided by financing activities		284			593
Net change in cash and cash equivalents		7,562			4,002
Cash and cash equivalents, beginning of period		20,159			9,819
Cash and cash equivalents, end of period	$	27,721		$	13,821

Cardiac Science Corporation and Subsidiaries
Reconciliation of GAAP Results to Non-GAAP Results (unaudited)
(in thousands)

	Reconciliation of Net Income to Adjusted EBITDA
	Three Months Ended						Three Months Ended
	June 30, 2008						June 30, 2007
				% of revenue						% of revenue
Net income	$	2,286			4.4	%	$	4,530			10.1	%
Depreciation and amortization		1,624			3.1	%		1,706			3.8	%
Interest income		(163	)		-0.3	%		(74	)		-0.2	%
Income tax expense		1,407			2.7	%		2,155			4.8	%
EBITDA		5,154			9.9	%		8,317			18.5	%
Stock-based compensation		488			0.9	%		562			1.3	%
Litigation and related expenses		—			0.0	%		2,029			4.5	%
Licensing income and litigation settlement		—			0.0	%		(6,000	)		-13.4	%
Adjusted EBITDA	$	5,642			10.8	%	$	4,908			10.9	%

	Reconciliation of Net Income to Adjusted EBITDA
	Six Months Ended						Six Months Ended
	June 30, 2008						June 30, 2007
				% of revenue						% of revenue
Net income	$	4,340			4.3	%	$	4,364			5.0	%
Depreciation and amortization		3,233			3.2	%		3,312			3.8	%
Interest income		(278	)		-0.3	%		(96	)		-0.1	%
Income tax expense		2,647			2.6	%		2,080			2.4	%
EBITDA		9,942			9.8	%		9,660			11.2	%
Stock-based compensation		1,046			1.0	%		1,175			1.4	%
Litigation and related expenses		—			0.0	%		3,717			4.3	%
Licensing income and litigation settlement		—			0.0	%		(6,000	)		-6.9	%
Adjusted EBITDA	$	10,988			10.9	%	$	8,552			9.9	%

	Reconciliation of Operating Income to Pro Forma Operating Income
	Three Months Ended					Three Months Ended
	June 30, 2008					June 30, 2007
			% of revenue						% of revenue
Operating income	$	3,773		7.2	%	$	6,269			14.0	%
Litigation and related expenses		—		0.0	%		2,029			4.5	%
Licensing income and litigation settlement		—		0.0	%		(6,000	)		-13.4	%
Pro forma operating income	$	3,773		7.2	%	$	2,298			5.1	%

	Reconciliation of Operating Income to Pro Forma Operating Income
	Six Months Ended					Six Months Ended
	June 30, 2008					June 30, 2007
			% of revenue						% of revenue
Operating income	$	6,794		6.7	%	$	5,859			6.8	%
Litigation and related expenses		—		0.0	%		3,717			4.3	%
Licensing income and litigation settlement		—		0.0	%		(6,000	)		-6.9	%
Pro forma operating income	$	6,794		6.7	%	$	3,576			4.1	%

	Reconciliation of Net Income to Pro Forma Net Income
	Three Months Ended					Three Months Ended
	June 30, 2008					June 30, 2007
			% of revenue						% of revenue
Net income	$	2,286		4.4	%	$	4,530			10.1	%
Litigation and related expenses		—		0.0	%		2,029			4.5	%
Licensing income and litigation settlement		—		0.0	%		(6,000	)		-13.4	%
Tax effect		—		0.0	%		1,169			2.6	%
Pro forma net income (loss)	$	2,286		4.4	%	$	1,728			3.8	%
Weighted average shares outstanding — diluted		23,246,240					23,283,471
Net income (loss) per share — diluted	$	0.10				$	0.07

	Reconciliation of Net Income to Pro Forma Net Income
	Six Months Ended					Six Months Ended
	June 30, 2008					June 30, 2007
			% of revenue						% of revenue
Net income	$	4,340		4.3	%	$	4,364			5.0	%
Litigation and related expenses		—		0.0	%		3,717			4.3	%
Licensing income and litigation settlement		—		0.0	%		(6,000	)		-6.9	%
Tax effect		—		0.0	%		567			0.7	%
Pro forma net income	$	4,340		4.3	%	$	2,648			3.1	%
Weighted average shares outstanding — diluted		23,277,135					23,187,206
Net income per share — diluted	$	0.19				$	0.11